Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids

被引：0
|
作者：
Talaulikar, Vikram Sinai [1 ]
Manyonda, Isaac [1 ]
机构：
[1] St Georges Hosp & Univ London, London SW17 0RE, England
来源：
WOMENS HEALTH | 2014年 / 10卷 / 06期
关键词：
fibroids; medical; myoma; SPRM; ulipristal acetate;
D O I：
10.2217/WHE.14.60
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Although it has been known for a long time that uterine fibroids respond to changes in sex steroid concentrations, it is the availability of selective progesterone receptor modulators such as ulipristal acetete that has provided the gynecologist with a novel option for medical management of uterine fibroids. Ulipristal acetate is presently licensed in Europe for use in women with symptomatic fibroids up to 3 months prior to surgery and has demonstrated good clinical efficacy and safety for this indication. Future trials will define the long-term safety of this drug and its role in medical management of uterine fibroids.
引用
收藏
页码：565 / 570
页数：6
相关论文
共 50 条
  • [1] The cost-effectiveness of ulipristal acetate tablets in treating patients with moderate to severe symptoms of uterine fibroids
    Nagy, Balazs
    Timar, Gyoergy
    Jozwiak-Hagymasy, Judit
    Kovacs, Gabor
    Meresz, Gergo
    Vamossy, Istvan
    Agh, Tomas
    Laszlo, Adam
    Voko, Zoltan
    Kalo, Zoltan
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2014, 175 : 75 - 81
  • [2] Effect of Ulipristal Acetate for Uterine Fibroids
    Deshpande, Preeti Suhas
    Deshpande, Suhas Suresh
    JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS, 2019, 8 (49): : 3675 - 3678
  • [3] Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids
    Donnez, Jacques
    Hudecek, Robert
    Donnez, Olivier
    Matule, Dace
    Arhendt, Hans-Joachim
    Zatik, Janos
    Kasilovskiene, Zaneta
    Dumitrascu, Mihai Cristian
    Fernandez, Herve
    Barlow, David H.
    Bouchard, Philippe
    Fauser, Bart C. J. M.
    Bestel, Elke
    Terrill, Paul
    Osterloh, Ian
    Loumaye, Ernest
    FERTILITY AND STERILITY, 2015, 103 (02) : 519 - 527
  • [4] Role of ethnicity in treating uterine fibroids with ulipristal acetate
    Murji, Ally
    Crosier, Rebecca
    Chow, Tiffany
    Ye, Xiang Y.
    Shirreff, Lindsay
    FERTILITY AND STERILITY, 2016, 106 (05) : 1165 - 1169
  • [5] Ulipristal Acetate: a Novel Option for the Medical Management of Symptomatic Uterine Fibroids
    Talaulikar, Vikram S.
    Manyonda, Isaac T.
    ADVANCES IN THERAPY, 2012, 29 (08) : 655 - 663
  • [6] Ulipristal Acetate: a Novel Option for the Medical Management of Symptomatic Uterine Fibroids
    Vikram S. Talaulikar
    Isaac T. Manyonda
    Advances in Therapy, 2012, 29 : 655 - 663
  • [7] The Clinical Pharmacology and Pharmacokinetics of Ulipristal Acetate for the Treatment of Uterine Fibroids
    Pohl, Oliver
    Zobrist, R. Howard
    Gotteland, Jean-Pierre
    REPRODUCTIVE SCIENCES, 2015, 22 (04) : 476 - 483
  • [8] The Clinical Pharmacology and Pharmacokinetics of Ulipristal Acetate for the Treatment of Uterine Fibroids
    Oliver Pohl
    R. Howard Zobrist
    Jean-Pierre Gotteland
    Reproductive Sciences, 2015, 22 : 476 - 483
  • [9] Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate
    Donnez, Jacques
    Donnez, Olivier
    Dolmans, Marie-Madeleine
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (12) : 1679 - 1686
  • [10] Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids
    Tafi, Emanuela
    Scala, Carolina
    Maggiore, Umberto Leone Roberti
    Bizzarri, Nicolo
    Candiani, Massimo
    Venturini, Pier Luigi
    Ferrero, Simone
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (06) : 965 - 977
12345